Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression

Journal of the American Society of Nephrology

Volumn 19, Issue 12, 2008, Pages 2437-2446

  Datta, Dipak ^a,b   Contreras, Alan G ^a,b   Grimm, Martin ^c   Waaga Gasser, Ana Maria ^c   Briscoe, David M ^a,b   Pal, Soumitro ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR3 A; CHEMOKINE RECEPTOR CXCR3 B; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PREVENTION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; KIDNEY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 57149115976     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2008040394     Document Type: Article

References (50)

1. Klee CB, Crouch TH, Krinks MH: Calcineurin: A calcium- and calmodulin-binding protein of the nervous system. Proc Natl Acad Sci U S A 76: 6270-6273, 1979
2. Klee CB, Ren H, Wang X: Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. J Biol Chem 273: 13367-13370, 1998
3. Graef IA, Chen F, Chen L, Kuo A, Crabtree GR: Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell 105: 863-875, 2001
4. Crabtree GR, Olson EN: NFAT signaling: Choreographing the social lives of cells. Cell 109[Suppl]: S67-S79, 2002
5. Hogan PG, Chen L, Nardone J, Rao A: Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 17: 2205-2232, 2003
6. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66: 807-815, 1991
7. Ponticelli C: Cyclosporine: From renal transplantation to autoimmune diseases. Ann N Y Acad Sci 1051: 551-558, 2005
8. Chow DK, Leong RW: The use of tacrolimus in the treatment of inflammatory bowel disease. Expert Opin Drug Saf 6: 479-485, 2007
9. Kaufman DB, Shapiro R, Lucey MR, Cherikh WS, Bustami RT, Dyke DB: Immunosuppression: practice and trends. Am J Transplant 4[Suppl 9]: 38-53, 2004
10. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M: Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397: 530-534, 1999
11. Guba M, Graeb C, Jauch KW, Geissler EK: Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 77: 1777-1782, 2004
12. Gutierrez-Dalmau A, Campistol JM: Immunosuppressive therapy and malignancy in organ transplant recipients: A systematic review. Drugs 67: 1167-1198, 2007
13. Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M: Malignancy in renal transplantation. J Am Soc Nephrol 15: 1582-1588, 2004
14. Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR: Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: A cohort study of 15,183 recipients. Am J Transplant 7: 2140-2151, 2007
15. Bustami RT, Ojo AO, Wolfe RA, Merion RM, Bennett WM, McDiarmid SV, Leichtman AB, Held PJ, Port FK: Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 4: 87-93, 2004
16. Jamil B, Nicholls K, Becker GJ, Walker RG: Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. Transplantation 68: 1597-1603, 1999
17. Molmenti EP, Nagata DE, Roden JS, Squires RH, Molmenti H, Fasola CG, Winick N, Tomlinson G, Lopez MJ, D'Amico L, Dyer HL, Savino AC, Sanchez EQ, Levy MF, Goldstein RM, Anderson JA, Klintmalm GB: Post-transplant lymphoproliferative syndrome in the pediatric liver transplant population. Am J Transplant 1: 356-359, 2001
18. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C: Cancer after kidney transplantation in the United States. Am J Transplant 4: 905-913, 2004
19. Maluccio M, Sharma V, Lagman M, Vyas S, Yang H, Li B, Suthanthiran M: Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 76: 597-602, 2003
20. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 8: 128-135, 2002
21. Koehl GE, Andrassy J, Guba M, Richter S, Kroemer A, Scherer MN, Steinbauer M, Graeb C, Schlitt HJ, Jauch KW, Geissler EK: Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 77: 1319-1326, 2004
22. Ohsawa I, Murakami T, Uemoto S, Kobayashi E: In vivo luminescent imaging of cyclosporin A-mediated cancer progression in rats. Transplantation 81: 1558-1567, 2006
23. Basu A, Contreras AG, Datta D, Flynn E, Zeng L, Cohen HT, Briscoe DM, Pal S: Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer. Cancer Res 68: 5689-5698, 2008
24. Zlotnik A, Yoshie O: Chemokines: A new classification system and their role in immunity. Immunity 12: 121-127, 2000
25. Segerer S: The role of chemokines and chemokine receptors in progressive renal diseases. Am J Kidney Dis 41: S15-S18, 2003
26. Balkwill F, Mantovani A: Inflammation and cancer: Back to Virchow? Lancet 357: 539-545, 2001
27. Proudfoot AE: Chemokine receptors: Multifaceted therapeutic targets. Nat Rev Immunol 2: 106-115, 2002
28. Datta D, Flaxenburg JA, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S: Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: Relevance for the development of human breast cancer. Cancer Res 66: 9509-9518, 2006
29. Viola A, Luster AD: Chemokines and their receptors: Drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 48: 171-197, 2008
30. Zlotnik A: Chemokines in neoplastic progression. Semin Cancer Biol 14: 181-185, 2004
31. Strieter RM, Belperio JA, Phillips RJ, Keane MP: CXC chemokines in angiogenesis of cancer. Semin Cancer Biol 14: 195-200, 2004
32. Luster AD, Leder P: IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 178: 1057-1065, 1993
33. Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, Witz IP, Ben-Baruch A: CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 67: 3396-3405, 2007
34. Walser TC, Rifat S, Ma X, Kundu N, Ward C, Goloubeva O, Johnson MG, Medina JC, Collins TL, Fulton AM: Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 66: 7701-7707, 2006
35. Suyama T, Furuya M, Nishiyama M, Kasuya Y, Kimura S, Ichikawa T, Ueda T, Nikaido T, Ito H, Ishikura H: Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma. Cancer 103: 258-267, 2005
36. Teichmann M, Meyer B, Beck A, Niedobitek G: Expression of the interferon-inducible chemokine IP-10 (CXCL10), a chemokine with proposed anti-neoplastic functions, in Hodgkin lymphoma and nasopharyngeal carcinoma. J Pathol 206: 68-75, 2005
37. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P: An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 197: 1537-1549, 2003
38. Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S: CXC chemokines: The regulatory link between inflammation and angiogenesis. Trends Immunol 25: 201-209, 2004
39. Kelsen SG, Aksoy MO, Yang Y, Shahabuddin S, Litvin J, Safadi F, Rogers TJ: The chemokine receptor CXCR3 and its splice variant are expressed in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 287: L584-L591, 2004
40. Romagnani P, Maggi L, Mazzinghi B, Cosmi L, Lasagni L, Liotta F, Lazzeri E, Angeli R, Rotondi M, Fili L, Parronchi P, Serio M, Maggi E, Romagnani S, Annunziato F: CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J Allergy Clin Immunol 116: 1372-1379, 2005
41. Dantal J, Pohanka E: Malignancies in renal transplantation: An unmet medical need. Nephrol Dial Transplant 22[Suppl 1]: i4 -i10, 2007
42. Sugie N, Fujii N, Danno K: Cyclosporin-A suppresses p53-dependent repair DNA synthesis and apoptosis following ultraviolet-B irradiation. Photodermatol Photoimmunol Photomed 18: 163-168, 2002
43. Kawada K, Hosogi H, Sonoshita M, Sakashita H, Manabe T, Shimahara Y, Sakai Y, Takabayashi A, Oshima M, Taketo MM: Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 26: 4679-4688, 2007
44. Furuya M, Suyama T, Usui H, Kasuya Y, Nishiyama M, Tanaka N, Ishiwata I, Nagai Y, Shozu M, Kimura S: Up-regulation of CXC chemokines and their receptors: Implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. Hum Pathol 38: 1676-1687, 2007
45. Wimmer CD, Rentsch M, Crispin A, Illner WD, Arbogast H, Graeb C, Jauch KW, Guba M: The janus face of immunosuppression: De novo malignancy after renal transplantation - The experience of the Transplantation Center Munich. Kidney Int 71: 1271-1278, 2007
46. Petrai I, Rombouts K, Lasagni L, Annunziato F, Cosmi L, Romanelli RG, Sagrinati C, Mazzinghi B, Pinzani M, Romagnani S, Romagnani P, Marra F: Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B. Int J Biochem Cell Biol 40:1764-1774, 2008
47. Kouroumalis A, Nibbs RJ, Aptel H, Wright KL, Kolios G, Ward SG: The chemokines CXCL9, CXCL10, and CXCL11 differentially stimulate G alpha i-independent signaling and actin responses in human intestinal myofibroblasts. J Immunol 175: 5403-5411, 2005
48. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard MC, Schall TJ: A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 203: 2201-2213, 2006
49. Ehlert JE, Addison CA, Burdick MD, Kunkel SL, Strieter RM: Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. J Immunol 173: 6234-6240, 2004
50. Connor KM, Hempel N, Nelson KK, Dabiri G, Gamarra A, Belarmino J, Van De Water L, Mian BM, Melendez JA: Manganese superoxide dismutase enhances the invasive and migratory activity of tumor cells. Cancer Res 67: 10260-10267, 2007